|
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study
|
28 July 2020 |
|
Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
|
27 July 2020 |
|
Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
|
27 July 2020 |
|
Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
|
14 July 2020 |
|
Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
|
01 July 2020 |
|
Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
|
11 May 2020 |
|
Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development
|
10 April 2020 |
|
Pfizer Vaccines launches global Centers of Excellence Network
|
23 January 2020 |
|
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
|
23 December 2019 |
|
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
|
02 December 2019 |
|
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
|
13 November 2019 |
|
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon
|
24 October 2019 |
|
Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
|
07 October 2019 |
|
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman
|
30 September 2019 |
|
Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina
|
29 August 2019 |
|
The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance
|
21 August 2019 |
|
Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine
|
29 July 2019 |
|
Pfizer completes acquisition of Therachon
|
05 July 2019 |
|
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development
|
07 June 2019 |
|
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
|
24 May 2019 |